Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that paired higher-than-approved doses of risankizumab with extended follow-up and found high early skin clearance alongside…
Continue Reading
News Source: medicalxpress.com
Leave a Reply